Literature DB >> 19575001

NAC is associated with additional alleviation of lung injury induced by invasive pulmonary aspergillosis in a neutropenic model.

Peng Xu1, Jie-Ming Qu, Jin-Fu Xu, Jing Zhang, Hong-Ni Jiang, Hui-Jun Zhang.   

Abstract

AIM: Neutropenic individuals are at high risk for invasive pulmonary aspergillosis (IPA), a life-threatening infection. To evaluate the therapeutic potential of antioxidants, IPA was induced in neutropenic mice and the effect of N-acetyl-l-cysteine (NAC) on oxidative stress levels and lung injury was analyzed.
METHODS: Mice were pretreated with three daily intraperitoneal injections of 150 mg/kg cyclophosphamide, followed by intratracheal inoculation with 4.5x10(6) conidia of Aspergillus fumigatus. The infected mice were then randomly assigned to an amphotericin B (AMB) group, an AMB plus NAC group, or an untreated control (C) group. In each group, the duration of treatment was 24, 48, or 72 h, and activities such as appearance, feeding, and dermal temperature were observed throughout the experiment. Sera and lung tissues were collected and analyzed by quantitative enzyme-linked immunosorbent assay (ELISA) for total protein, superoxide dismutase (SOD), malondialdehyde (MDA), tumor necrosis factor-alpha (TNF-alpha), and interleukin-10 (IL-10) levels. The wet/dry weight ratio of the lung was also calculated and lung sections were stained with hematoxylin-eosin for pathological examination and with methenamine silver stain for fungus detection.
RESULTS: Compared with the mice untreated with NAC, mice in the AMB plus NAC group had increased SOD and reduced MDA levels both systemically and locally at 24, 48, and 72 h after inoculation with conidia. NAC treatment also decreased the pulmonary protein content at 48 and 72 h and the lung wet/dry weight ratio at 24 and 48 h. Additionally, NAC enhanced pulmonary production of TNF-alpha and IL-10 at 24 h and 48 h.
CONCLUSION: In combination with antifungal therapy, NAC treatment can alleviate oxidative stress and lung injury associated with IPA in neutropenic mice.Acta Pharmacologica Sinica (2009) 30: 980-986; doi: 10.1038/aps.2009.83.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19575001      PMCID: PMC4006662          DOI: 10.1038/aps.2009.83

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  37 in total

1.  A stain for fungi in tissue sections and smears using Gomori's methenamine-silver nitrate technic.

Authors:  R G GROCOTT
Journal:  Am J Clin Pathol       Date:  1955-08       Impact factor: 2.493

2.  Role of collectins in innate immunity against aspergillosis.

Authors:  T Madan; S Kaur; S Saxena; M Singh; U Kishore; S Thiel; K B M Reid; P U Sarma
Journal:  Med Mycol       Date:  2005-05       Impact factor: 4.076

3.  Cytokine profiling of pulmonary aspergillosis.

Authors:  H Sambatakou; V Pravica; I V Hutchinson; D W Denning
Journal:  Int J Immunogenet       Date:  2006-08       Impact factor: 1.466

Review 4.  Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients.

Authors:  F Reichenberger; J M Habicht; A Gratwohl; M Tamm
Journal:  Eur Respir J       Date:  2002-04       Impact factor: 16.671

5.  Inhaled activated protein C attenuates lung injury induced by aerosolized endotoxin in mice.

Authors:  Anastasia Kotanidou; Heleni Loutrari; Evangelos Papadomichelakis; Constantinos Glynos; Christina Magkou; Apostolos Armaganidis; Andreas Papapetropoulos; Charis Roussos; Stylianos E Orfanos
Journal:  Vascul Pharmacol       Date:  2006-07-25       Impact factor: 5.773

6.  Effect of amphotericin B lipid formulation on immune response in aspergillosis.

Authors:  S Saxena; P K Bhatnagar; P C Ghosh; P U Sarma
Journal:  Int J Pharm       Date:  1999-10-15       Impact factor: 5.875

7.  TLRs govern neutrophil activity in aspergillosis.

Authors:  Silvia Bellocchio; Silvia Moretti; Katia Perruccio; Francesca Fallarino; Silvia Bozza; Claudia Montagnoli; Paolo Mosci; Grayson B Lipford; Lucia Pitzurra; Luigina Romani
Journal:  J Immunol       Date:  2004-12-15       Impact factor: 5.422

Review 8.  Signalling and oxidant adaptation in Candida albicans and Aspergillus fumigatus.

Authors:  Neeraj Chauhan; Jean-Paul Latge; Richard Calderone
Journal:  Nat Rev Microbiol       Date:  2006-06       Impact factor: 60.633

9.  Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin.

Authors:  John R Graybill; Rosie Bocanegra; Gloria M Gonzalez; Laura K Najvar
Journal:  J Antimicrob Chemother       Date:  2003-09-12       Impact factor: 5.790

10.  Characterisation of the phagocytic uptake of Aspergillus fumigatus conidia by macrophages.

Authors:  Kathrin Luther; Manfred Rohde; Katrin Sturm; Andrea Kotz; Jürgen Heesemann; Frank Ebel
Journal:  Microbes Infect       Date:  2007-11-17       Impact factor: 2.700

View more
  2 in total

1.  Antifungal and antihepatotoxic effects of sepia ink extract against oxidative stress as a risk factor of invasive pulmonary aspergillosis in neutropenic mice.

Authors:  Sohair R Fahmy; Amel M Soliman; Enas M Ali
Journal:  Afr J Tradit Complement Altern Med       Date:  2014-04-03

2.  Erythropoietin Combined with Liposomal Amphotericin B Improves Outcome during Disseminated Aspergillosis in Mice.

Authors:  Nathalie Rousseau; Stephane Picot; Anne-Lise Bienvenu
Journal:  Front Immunol       Date:  2014-10-14       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.